Literature DB >> 22552011

Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.

Matthias Kloor1, Cathrin Huth, Anita Y Voigt, Axel Benner, Peter Schirmacher, Magnus von Knebel Doeberitz, Hendrik Bläker.   

Abstract

BACKGROUND: Lynch syndrome is an inherited tumour predisposition syndrome caused by germline mutations of DNA mismatch repair (MMR) genes. Mutation carriers have a high risk of developing colorectal cancer, but do not present with polyposis, a typical feature of other colorectal cancer syndromes such as familial adenomatous polyposis, in which polyposis reflects the high frequency of biallelic APC gene inactivation. We asked whether in Lynch syndrome biallelic inactivation of MMR genes occurred at a similar frequency to that of APC gene, and whether MMR inactivation resulted in detectable lesions within the intestinal mucosa.
METHODS: Resections done for small and large bowel cancer between January, 2002, and January, 2011, were retrieved. We systematically analysed non-tumorous mucosa from carriers of a Lynch syndrome mutation (set 1: ten patients) and control patients without Lynch syndrome (set 1: nine patients) for MMR protein expression (MLH1, MSH2, and EPCAM) with immunohistochemistry. We validated the findings in an independent sample set (set 2: 30 Lynch syndrome patients, 79 controls). We did an analysis of microsatellite instability by PCR analysis to test lesions for mismatch repair deficiency. We applied a Poisson regression model to analyse the distribution of MMR-deficient crypt foci counts and a Fisher's exact test to compare the prevalence of these foci between mutation carriers and control patients.
FINDINGS: 20 crypt foci with no MMR protein expression were detected in 20·1 cm(2) of non-tumorous mucosa from Lynch syndrome patients (set 1), an additional five were detected upon resectioning of two samples. In an independent validation set (set 2), two MMR-deficient crypt foci were noted in 2·2 cm(2) of mucosa. No MMR-deficient crypt foci were noted in non-tumorous mucosa from control patients without evidence for Lynch syndrome (set 1: 3·7 cm(2), set 2: 4·8 cm(2)). Microsatellite instability was detected in all seven MMR-deficient crypt foci analysed. A subset of these foci displayed unusual architectural and cytological abnormalities, although they had no polypous or adenomatous appearance.
INTERPRETATION: We identified a novel type of lesion, the MMR-deficient crypt focus, as the manifestation of biallelic MMR gene inactivation in Lynch syndrome. The abundance of MMR-deficient crypt foci indicates a high frequency of biallelic MMR gene inactivation, which is in sharp contrast with the low number of clinically manifest cancers in Lynch syndrome. This discrepancy suggests that most MMR-deficient crypt foci do not progress to cancer. We propose Lynch syndrome as a unique model syndrome for studying initial steps of MMR deficiency, tumour initiation and, possibly, elimination. FUNDING: German Cancer Aid and German Research Foundation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552011     DOI: 10.1016/S1470-2045(12)70109-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  41 in total

Review 1.  Recent advances in Lynch syndrome.

Authors:  Leah H Biller; Sapna Syngal; Matthew B Yurgelun
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

2.  High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.

Authors:  Jonas Janikovits; Meike Müller; Julia Krzykalla; Sandrina Körner; Fabian Echterdiek; Bernd Lahrmann; Niels Grabe; Martin Schneider; Axel Benner; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Oncoimmunology       Date:  2017-11-06       Impact factor: 8.110

3.  Colonoscopy in Lynch syndrome: the need for a new quality score.

Authors:  Jurjen J Boonstra; Wouter H de Vos Tot Nederveen Cappel; Alexandra M J Langers; Hedwig van der Sluis; James H Hardwick; Hans F A Vasen
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

4.  DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome.

Authors:  Rish K Pai; Beth Dudley; Eve Karloski; Randall E Brand; Neil O'Callaghan; Christophe Rosty; Daniel D Buchanan; Mark A Jenkins; Stephen N Thibodeau; Amy J French; Noralane M Lindor; Reetesh K Pai
Journal:  Mod Pathol       Date:  2018-06-08       Impact factor: 7.842

Review 5.  EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients.

Authors:  Marjolijn J L Ligtenberg; Roland P Kuiper; Ad Geurts van Kessel; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

6.  Different in vivo and in vitro transformation of intestinal stem cells in mismatch repair deficiency.

Authors:  K Keysselt; T Kreutzmann; K Rother; C Kerner; K Krohn; J Przybilla; P Buske; H Löffler-Wirth; M Loeffler; J Galle; G Aust
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

Review 7.  Unravelling biology and shifting paradigms in cancer with single-cell sequencing.

Authors:  Timour Baslan; James Hicks
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

8.  Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients.

Authors:  Serena Wong; Pei Hui; Natalia Buza
Journal:  Mod Pathol       Date:  2020-01-13       Impact factor: 7.842

Review 9.  [Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options].

Authors:  M Kloor
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

10.  Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case.

Authors:  Jinru Shia; Zsofia K Stadler; Martin R Weiser; Efsevia Vakiani; Robin Mendelsohn; Arnold J Markowitz; Moshe Shike; C Richard Boland; David S Klimstra
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.